Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals

AIDS

Volumn 16, Issue 11, 2002, Pages 1511-1519

  Simon, Viviana ^a   Vanderhoeven, Jeroen ^a   Hurley, Arlene ^a   Ramratnam, Bharat ^a,c   Louie, Michael ^a   Dawson, Keith ^b   Parkin, Neil ^b   Boden, Daniel ^a,c   Markowitz, Martin ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Acute infection; Drug resistance; HIV 1; Phenotypic drug resistance; Resistance mutations

Indexed keywords

ABACAVIR; ASPARTIC ACID; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERINE; STAVUDINE; THYMIDINE; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AMINO ACID SUBSTITUTION; ARTICLE; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; ADULT; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; ETHNIC GROUP; GENETICS; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MUTATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; MALE; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS;

EID: 0037178323     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200207260-00008     Document Type: Article

References (26)

1. The effect of commencing combination antiretroviral therapy soon after human immunocleficiency virus type 1 infection on viral replication and antiviral immune responses
2. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
3. Immune control of HIV-1 after early treatment of acute infection
4. Antiretroviral resistance and response to initial therapy among recently HIV-infected subjects in North America
5. Transmission of antiretroviral-drug-resistant HIV-1 variants
6. HIV-1 drug resistance in newly infected individuals
7. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
8. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study
9. Predicting the unpredictable: Transmission of drug-resistant HIV
10. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom
11. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
12. Mutations in retroviral genes associated with drug reistance: 1999-2000 Update
13. Human immunodeficiency virus type-1 reverse-transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population
14. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
15. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant
16. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1-infected patients
17. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
18. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons
19. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
20. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy
21. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
22. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
23. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy
24. Polymorphisms in p6/p6* of HIV-1 Gag are associated with hypersusceptibility to protease inhibitors
25. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors
26. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel